Truist raised the firm’s price target on Vericel to $39 from $33 and keeps a Hold rating on the shares. The analyst cites the company’s Q3 revenue upside, even though “investors may have been looking for a bit more MACI upside”. Truist adds that it still sees Vericel accelerating growth in FY24, but also remains on the sidelines as this is already reflected in valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VCEL:
- Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
- Vericel raises 2023 revenue view $192.5M-$197.5M from $190M-$197M
- Vericel reports Q3 EPS (8c), consensus (12c)
- Vericel to Present at the Stephens Annual Investment Conference
- Is VCEL a Buy, Before Earnings?
